Glioma Immunotherapy: Advances and Challenges for Spinal Cord Gliomas

다국어 초록 (Multilingual Abstract)

Spinal cord gliomas are rare entities that often have limited surgical options. Immunotherapy has shown promise in intracranial gliomas with some research suggesting benefit for spinal cord gliomas. A focused review of immunotherapies that have been investigated in spinal cord gliomas was performed. The primary methods of immunotherapy investigated in spinal cord gliomas include immune checkpoint inhibitors, adoptive T-cell therapies, and vaccine strategies. There are innumerable challenges that must be overcome to effectively apply immunotherapeutic strategies to the spinal cord gliomas including low incidence, few antigenic targets, the blood spinal cord barrier, the immunosuppressive tumor microenvironment and neurotoxic treatment effects. Nonetheless, research has suggested ways to overcome these challenges and treatments have been effective in case reports for metastatic non-small cell lung cancer, melanoma, midline glioma and glioblastoma. Current therapies for spinal cord gliomas are markedly limited. Further research is needed to determine if the success of immunotherapy for intracranial gliomas can be effectively applied to these unique tumors.

참고문헌 (Reference)

1 Pardi N, "mRNA vaccines-a new era in vaccinology" 17 : 261-279, 2018

2 MOLE RH, "Whole body irradiation; radiobiology or medicine" 26 : 234-241, 1953

3 Weller M, "Vaccine-based immunotherapeutic approaches to gliomas and beyond" 13 : 363-374, 2017

4 Ellis JA, "Unique microenvironmental responses to PDGF stimulation in brain and spinal cord gliomas determine tumor phenotype" 123 : 27-33, 2015

5 Wu T, "Tumor microenvironment and therapeutic response" 387 : 61-68, 2017

6 Hernández-Durán S, "The role of stereotactic radiosurgery in the treatment of intramedullary spinal cord neoplasms : a systematic literature review" 39 : 175-183, 2016

7 Chai RC, "The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation" 8 : 40-, 2020

8 Chan KM, "The histone H3. 3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression" 27 : 985-990, 2013

9 Rahman M, "The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma" 127 : 123-131, 2017

10 Qian J, "The IFN-γ/PD-L1 axis between T cells and tumor microenvironment : hints for glioma anti-PD-1/PD-L1 therapy" 15 : 290-, 2018

11 Louis DN, "The 2016 World Health Organization Classification of Tumors of the Central Nervous System : a summary" 131 : 803-820, 2016

12 Mitchell DA, "Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients" 519 : 366-369, 2015

13 Houot R, "T-cell-based Immunotherapy : adoptive cell transfer and checkpoint inhibition" 3 : 1115-1122, 2015

14 Kwok D, "T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment" 147 : 281-295, 2020

15 Parkhurst MR, "T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis" 19 : 620-626, 2011

16 Chow KK, "T cells redirected to EphA2 for the immunotherapy of glioblastoma" 21 : 629-637, 2013

17 Gustafson MP, "Systemic immune suppression in glioblastoma : the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone" 12 : 631-644, 2010

18 Sayour EJ, "Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles" 6 : e1256527-, 2016

19 Brown CE, "Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells" 18 : 2199-2209, 2012

20 Alvi MA, "Spinal cord high-grade infiltrating gliomas in adults : clinico-pathological and molecular evaluation" 32 : 1236-1243, 2019

21 Wang YZ, "Spinal cord diffuse midline gliomas with H3 K27m-mutant : clinicopathological features and prognosis" 89 : 300-307, 2021

22 Parsa AT, "Spinal cord and intradural-extraparenchymal spinal tumors : current best care practices and strategies" 69 : 291-318, 2004

23 Mitchell DA, "Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma" 10 : 10-18, 2008

24 Prockop LD, "Selective permeability of [3H]-D-mannitol and [14C]-carboxyl-inulin across the blood-brain barrier and blood-spinal cord barrier in the rabbit" 18 : 221-226, 1995

25 Weller M, "Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma(ACT IV) : a randomised, double-blind, international phase 3 trial" 18 : 1373-1385, 2017

26 Brown CE, "Regression of glioblastoma after chimeric antigen receptor T-cell therapy" 375 : 2561-2569, 2016

27 Phillips KA, "Regression of an intramedullary spinal cord metastasis with a checkpoint inhibitor : a case report" 6 : 275-280, 2017

28 Pardi N, "Recent advances in mRNA vaccine technology" 65 : 14-20, 2020

29 Reardon DA, "Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma : CheckMate 143" 19 (19): iii21-, 2017

30 McNamara MA, "RNA-Based vaccines in cancer immunotherapy" 2015 : 794528-, 2015

31 BerghoffAS, "Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma" 17 : 1064-1075, 2015

32 Milano MT, "Primary spinal cord glioma : a Surveillance, Epidemiology, and End Results database study" 98 : 83-92, 2010

33 Ogunlade J, "Primary spinal astrocytomas : a literature review" 11 : e5247-, 2019

34 Mount CW, "Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas" 24 : 572-579, 2018

35 Quattrocchi KB, "Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas" 45 : 141-157, 1999

36 Kreisl TN, "Phase II trial of singleagent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma" 27 : 740-745, 2009

37 Sayour EJ, "Personalized tumor RNA loaded lipid-nanoparticles prime the systemic and intratumoral milieu for response to cancer immunotherapy" 18 : 6195-6206, 2018

38 Pan W, "Permeability of the bloodbrain and blood-spinal cord barriers to interferons" 76 : 105-111, 1997

39 Balch CM, "Patterns of human tumor-infiltrating lymphocytes in 120 human cancers" 125 : 200-205, 1990

40 Nduom EK, "PD-L1 expression and prognostic impact in glioblastoma" 18 : 195-205, 2016

41 Calinescu AA, "Overview of current immunotherapeutic strategies for glioma" 7 : 1073-1104, 2015

42 Liu Y, "Novel multifunctional polyethylene glycol-transactivating-transduction proteinmodified liposomes cross the blood-spinal cord barrier after spinal cord injury" 18 : 420-429, 2010

43 Chheda ZS, "Novel and shared neoantigen derived from histone 3 variant H3. 3K27M mutation for glioma T cell therapy" 215 : 141-157, 2018

44 Keskin DB, "Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial" 565 : 234-239, 2019

45 Schalper KA, "Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma" 25 : 470-476, 2019

46 Cloughesy TF, "Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma" 25 : 477-486, 2019

47 Hodges TR, "Mutational burden, immune checkpoint expression, and mismatch repair in glioma : implications for immune checkpoint immunotherapy" 19 : 1047-1057, 2017

48 Mut M, "Metastasis to nervous system : spinal epidural and intramedullary metastases" 75 : 43-56, 2005

49 Mueller S, "Mass cytometry detects H3. 3K27M-specific vaccine responses in diffuse midline glioma" 130 : 6325-6337, 2020

50 Ellezam B, "Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas" 124 : 449-451, 2012

51 Mineo JF, "Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma" 85 : 281-287, 2007

52 Raco A, "Long-term follow-up of intramedullary spinal cord tumors : a series of 202 cases" 56 : 972-981, 2005

53 Hochart A, "Long survival in a child with a mutated K27M-H3. 3 pilocytic astrocytoma" 2 : 439-443, 2015

54 Donovan LK, "Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma" 26 : 720-731, 2020

55 Ge S, "Isolation and culture of microvascular endothelial cells from murine spinal cord" 177 : 209-214, 2006

56 Glitza IC, "Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma : a case report" 3 : 1201-1206, 2015

57 Hanson LR, "Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease" 9 (9): S5-, 2008

58 McCormick PC, "Intramedullary ependymoma of the spinal cord" 72 : 523-532, 1990

59 Frey B, "Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation-implications for cancer therapies" 19 : 1751-1764, 2012

60 Karikari IO, "Impact of tumor histology on resectability and neurological outcome in primary intramedullary spinal cord tumors : a singlecenter experience with 102 patients" 76 (76): S4-S13, 2015

61 Choi BD, "Immunotherapy for glioblastoma : adoptive T-cell strategies" 25 : 2042-2048, 2019

62 Jackson CM, "Immunotherapy for brain cancer : recent progress and future promise" 20 : 3651-3659, 2014

63 Sampson JH, "Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma" 28 : 4722-4729, 2010

64 Garber ST, "Immune checkpoint blockade as a potential therapeutic target : surveying CNS malignancies" 18 : 1357-1366, 2016

65 Cameron BJ, "Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells" 5 : 197ra103-, 2013

66 Yan H, "IDH1 and IDH2 mutations in gliomas" 360 : 765-773, 2009

67 Sturm D, "Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma" 22 : 425-437, 2012

68 Gessi M, "High frequency of H3F3A(K27M)mutations characterizes pediatric and adult high-grade gliomas of the spinal cord" 130 : 435-437, 2015

69 Ahmed N, "HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma : a phase 1 dose-escalation trial" 3 : 1094-1101, 2017

70 Ahmed N, "HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors" 16 : 474-485, 2010

71 Sampson JH, "Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma" 13 : 324-333, 2011

72 Reardon DA, "Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model" 4 : 124-135, 2016

73 Nagaishi M, "Genetic mutations in high grade gliomas of the adult spinal cord" 33 : 267-269, 2016

74 Johnson LA, "Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen" 114 : 535-546, 2009

75 Jarboe JS, "Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme : implications for targeted therapies" 67 : 7983-7986, 2007

76 Melero I, "Evolving synergistic combinations of targeted immunotherapies to combat cancer" 15 : 457-472, 2015

77 Rodig N, "Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis" 33 : 3117-3126, 2003

78 Reardon DA, "Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma : the CheckMate 143 phase 3 randomized clinical trial" 6 : 1003-1010, 2020

79 Sampson JH, "EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss" 20 : 972-984, 2014

80 Wainwright DA, "Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors" 20 : 5290-5301, 2014

81 Schwartzentruber J, "Driver mutations in histone H3. 3 and chromatin remodelling genes in paediatric glioblastoma" 482 : 226-231, 2012

82 Zagzag D, "Downregulation of major histocompatibility complex antigens in invading glioma cells : stealth invasion of the brain" 85 : 328-341, 2005

83 Schellinger KA, "Descriptive epidemiology of primary spinal cord tumors" 87 : 173-179, 2008

84 Duong LM, "Descriptive epidemiology of malignant and nonmalignant primary spinal cord, spinal meninges, and cauda equina tumors, United States, 2004-2007" 118 : 4220-4227, 2012

85 Berger TG, "Dendritic cell-based immunotherapy" 276 : 163-197, 2003

86 Thorne RG, "Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration" 127 : 481-496, 2004

87 McGranahan T, "Current state of immunotherapy for treatment of glioblastoma" 20 : 24-, 2019

88 Min L, "Corticosteroids and immune checkpoint blockade" 7 : 521-522, 2015

89 Itakura G, "Control of the survival and growth of human glioblastoma grafted into the spinal cord of mice by taking advantage of immunorejection" 24 : 1299-1311, 2015

90 Zhang YW, "Clinicopathological characteristics and survival of spinal cord astrocytomas" 9 : 6996-7006, 2020

91 Lebrun L, "Clinical, radiological and molecular characterization of intramedullary astrocytomas" 8 : 128-, 2020

92 Engelhard HH, "Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges, or cauda equina" 13 : 67-77, 2010

93 Meyronet D, "Characteristics of H3 K27M-mutant gliomas in adults" 19 : 1127-1134, 2017

94 Wikstrand CJ, "Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII" 57 : 4130-4140, 1997

95 Morgan RA, "Cancer regression and neurological toxicity following anti-MAGEA3TCR gene therapy" 36 : 133-151, 2013

96 Simoni Y, "Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates" 557 : 575-579, 2018

97 Brown CE, "Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+T cells in patients with recurrent glioblastoma" 21 : 4062-4072, 2015

98 Friedman HS, "Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma" 27 : 4733-4740, 2009

99 Shankar GM, "BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology" 131 : 147-150, 2016

100 Jha P, "Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas" 39 : 413-424, 2019

101 Wongthida P, "Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors" 22 : 1757-1770, 2020

102 Banan R, "Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27Mmutant" 5 : 98-, 2017

103 O’Rourke DM, "A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma" 9 : eaaa0984-, 2017

104 Schuster J, "A phase II, multicenter trial of rindopepimut(CDX-110)in newly diagnosed glioblastoma : the ACT III study" 17 : 854-861, 2015